In a move which has baffled some and angered others, Canada Health has approved influenzinium, a nosode as a vaccine for flu. At a time that many consider critical for public health and vaccination programs, this move has caused outrage in the scientific community. Our editor inspects the issues surrounding this controversial topic. Full Article »

In this recent interview, Johannes Schoen, Boehringer Ingelheim speaks to Pharma IQ, following facilitating the "Anti-Counterfeiting: Falsified Medicines Directive and beyond" roundtable. Schoen discusses the outcomes of the roundtable and shares best practices for preparing for the Falsified Medicines Directive. Full Video »

Sonia Poli, VP for Non Clinical Development at Addex Therapeutics, a small biotech built in Geneva explains how the new FDA and EMA guidelines will impact their business. She looks at the daily challenges they are faced with and stresses the importance of having highly valuated assays which will translate into clinical data. Full Podcast »

One of the most important developments to come out of the new EU Pharmacovigilance regulations is the requirement for the preparation of Risk Management Plans (RMP) for all new submissions including generic submissions, Regulatory Expert and Columnist, Deepa Arora explains. Full Column »

Improving post-marketing drug safety occupies the top spot in the list of priorities of regulators, and therefore, drug companies and the entire pharmaceutical sector. Creating robust risk management plans is therefore a key to improving safety in Asia, discover the key challenges that must be overcome to make that a reality. Full Whitepaper »